Satyan Chintawar
COO and Co-founder @Biolligence
Signup · Get unlimited contacts
WORK HISTORY
COO and Co-founder @Biolligence
Oxford, GB
We are developing cutting-edge, human-relevant technologies to tackle one of the biggest challenges in drug discovery: Toxicity. Our innovative approach generates population-based human data early in the development process.This paves the way for a faster, more reliable path to precision clinical trials, ensuring therapies that are safer, more effective, and tailored to the diverse needs of human populations.
EDUCATION
Université libre de Bruxelles
PhD, Neuroscience
Savitribai Phule Pune University
M.Pharm., Pharmacology
Nagpur University
B.Pharm., Pharmaceutics, Pharmacology, Pharmaceutical chemistry
SKILLS
ABOUT SATYAN CHINTAWAR
I co-founded Oxford StemTech and Biolligence, focusing on iPSC-based models for drug efficacy and safety testing. My expertise lies in bridging cutting-edge stem cell technologies with AI-driven drug discovery, helping to advance safer and more effective therapeutics.At Oxford StemTech, we leverage human iPSC-derived models to improve preclinical drug screening and disease modeling. Meanwhile, at Biolligence, we harness AI and large-scale human toxicity datasets to enhance predictive toxicology and reduce drug failures in clinical trials.Passionate about translating scientific innovation into real-world impact, I am always open to collaborations and discussions on drug discovery, iPSC modeling, and AI-driven safety assessment. Let’s connect!
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.